SparX Group has Initiated a Phase 1 Trial of its First Organically Developed Candidate, SPX-101
- Monday, January 17, 2022, 7:30
- Environment
- Add a comment
CHICAGO, Jan. 17, 2022 /PRNewswire/ — With a mission of “Bolstering human immunity by utilizing empowered antibody therapies”, the SparX Group is rapidly becoming a significant player in the field of discovering unique therapeutic target combinations and development of novel bispecific…
About the Author
adminasapcorp has written 41608 stories on this site.